The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index.
Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
Open accessAbstract
OBJECTIVE: Early initiation of intensive diabetes therapy aimed at achieving near-normal glycemia reduces the early development of vascular complications in type 1 diabetes. We now assess whether intensive therapy compared with conventional therapy during the Diabetes Control and Complications Trial (DCCT) affected the incidence of cardiovascular disease over 30 years of follow-up. RESEARCH DESIGN AND METHODS: The DCCT randomly assigned 1,441 patients with type 1 diabetes to intensive versus conventional therapy for a mean of 6.5 years, after which 93% were subsequently monitored during the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Cardiovascular disease (nonfatal myocardial infarction and stroke, cardiovascular death, confirmed angina, congestive heart failure, and coronary artery revascularization) was adjudicated using standardized measures. RESULTS: During 30 years of follow-up in DCCT and EDIC, 149 cardiovascular disease events occurred in 82 former intensive treatment group subjects versus 217 events in 102 former conventional treatment group subjects. Intensive therapy reduced the incidence of any cardiovascular disease by 30% (95% CI 7, 48; P = 0.016), and the incidence of major cardiovascular events (nonfatal myocardial infarction, stroke, or cardiovascular death) by 32% (95% CI −3, 56; P = 0.07). The lower HbA1c levels during the DCCT/EDIC statistically account for all of the observed treatment effect on cardiovascular disease risk. Increased albuminuria was also independently associated with cardiovascular disease risk. CONCLUSIONS: Intensive diabetes therapy during the DCCT (6.5 years) has long-term beneficial effects on the incidence of cardiovascular disease in type 1 diabetes that persist for up to 30 years.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In the post-DCCT follow-up of the EDIC cohort, participants previously randomized to the intensive treatment arm had a significant 57% reduction in the risk of the composite outcome of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death compared with those previously randomized to the standard treatment arm (58).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An HbA1c of 7.0% or greater puts people with diabetes at risk of developing macrovascular and microvascular complications, whereas a HbA1c less than 7.0% or reducing HbA1c by 1.0% prevents complications [5,6].”
From One drop | Mobile on iPhone and apple watch: an evaluation of hbA1c improvement associated with tracking self-care (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“An HbA1c of 7.0% or greater puts people with diabetes at risk of developing macrovascular and microvascular complications, whereas a HbA1c less than 7.0% or reducing HbA1c by 1.0% prevents complications [5,6].”
From One drop | Mobile on iPhone and apple watch: an evaluation of hbA1c improvement associated with tracking self-care (2017) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the DCCT cohort, there was a significant reduction in CV outcomes (42%), nonfatal myocardial infarct (MI), stroke and CV death (57%), as well as all-cause mortality (33%) in previously intensively treated participants compared with those who were previously in the standard arm (17)(18)(19).”
From Targets for Glycemic Control (2018) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These benefits persisted beyond the end of the trial despite equivalent glucose levels in the two groups (HbA 1c 8% [64 mmol/mol]) in the posttrial period; furthermore, reductions in incident cardiovascular disease and mortality in the intensively treated group emerged with time (40).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [40]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“The landmark Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications studies have demonstrated that intensive insulin therapy reduces the risk of both micro-and macro-vascular complications in people with T1D.1,2”
From Effectiveness of Semaglutide and Tirzepatide in Overweight and Obese Adults with Type 1 Diabetes (2025) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, longer-term epidemiological follow-up of these studies also showed a pattern of CVD benefit (58-60).”
From 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. (2026) · cites this paper as [58]
The cited source says what the claim attributes to it.
In the citing paper
“The importance of glycemic management was demonstrated convincingly by the DCCT (39) and the Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up study (40).”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The glycemic control portion of the trial was prematurely terminated after 3.5 years due to higher mortality (1.41% vs. 1.14% per year, HR 1.22) associated with assignment to the intensive-treatment arm (19,20).”
From Targets for Glycemic Control (2018) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Self-citationThe Statistical Analysis of Failure Time Data.
Aitkin, M. A., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,875
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Self-citation10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Self-citationIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Self-citation
Flagged first, then by citations
1 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Backlund, 2003, Validation of deaths and reported cardiovascular cerebrovascular events (Abstract). Control Clin Trials, 23
Cited by
Sorted by citations
Items 601–700 of 712
Baruqui, R. R., Ferreira, L. V., Assú, G. F. G. C., Firmo, C. R., Ezequiel, D. G. A., & Leal, C. T. D. S. (2022) · HU Revista · doi:10.34019/1982-8047.2021.v47.34087
Reynaud, R., Bendelac, N., & Coutant, R. (2018) · Elsevier eBooks · doi:10.1016/b978-2-294-74942-1.00009-4
Aronow, W. S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.735910698.793566214
Danne, T., & Ziegler, R. (2018) · Springer Reference Medizin · doi:10.1007/978-3-662-52794-8_15-1
Désordres glycémiques et complications diabétiques : physiopathologie
Monnier, L., & Colette, C. (2019) · Elsevier eBooks · doi:10.1016/b978-2-294-75889-8.00009-9
23 gennaio 2022: 100 anni fa il miracolo della terapia insulinica che continua oggi
Bolli, G. B., Porcellati, F., Lucidi, P., & Fanelli, C. G. (2022) · il Diabete · doi:10.30682/ildia2201a
The cost of control: Cost-effectiveness analysis of hybrid closed-loop therapy in youth
Pease, A., Callander, E. J., Zomer, E., Abraham, M. B., Davis, E. A., Jones, T. W., Liew, D., & Zoungas, S. (2022) · doi:10.2337/figshare.20063300
Paterson, K. (2022) · doi:10.1002/9781119785033.ch7
Bernard Zinman: A Canadian Clinician Scientist Changing the Management of Diabetes
Drucker, D. J. (2022) · Diabetes Care · doi:10.2337/dci22-0017
Jain, A., Kohli, K. P., & Kumar, S. (2022) · Indian Journal Of Applied Research · doi:10.36106/ijar/5804670
Prise en charge du diabète de type 1 chez les adultes en France : l’étude SAGE
Renard, É., Nevoret, C., Borot, S., Delemer, B., Mohammedi, K., Sultan, A., Bahloul, A., Benkhelil, A., Detournay, B., & Penfornis, A. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.09.001
Huang, M.-F., Yuan, X., Zeng, X., Zhang, Z.-Y., Xia, Q., & Zhi-yu, Z. H. O. U. (2022) · Research Square · doi:10.21203/rs.3.rs-2044225/v1
Nationally Subsidized Continuous Glucose Monitoring: A Cost-Effectiveness Analysis
Pease, A., Zoungas, S., Callander, E. J., Jones, T. W., Johnson, S. R., Holmes-Walker, D. J., Bloom, D. E., Davis, E. A., & Zomer, E. (2022) · doi:10.2337/figshare.20668551.v1
Zhou, F., Deng, J., Banfield, L. E., Thabane, L., Sadeghirad, B., & Samaan, M. C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-065287
Plummer, E. S. (2022) · American Diabetes Association eBooks · doi:10.2337/9781580407700.ch06
Secondary Diseases of the Kidney
Natale, P., Wong, M. G., Strippoli, G. F., Tunnicliffe, D. J., Cooper, T. E., & Pollock, C. A. (2022) · Wiley eBooks · doi:10.1002/9781119105954.ch24
Efficience et précision du contrôle glycémique dans le diabète : symphonie inachevée ?
Monnier, L., Halimi, S., & Colette, C. (2022) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2022.11.005
Type 1 diabetes mellitus and cardiovascular risk: A short review
Kitsios, K., Trakatelli, C., Sarigianni, M., Kyriazidou, Α., Aroutsidis, F., Mastrogiannis, Κ., & Kotsis, V. (2022) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1039
Session Three: Innovating Beyond Glucose Control in Diabetes Care
Michel, L. (2017) · EMJ Diabetes · doi:10.33590/emjdiabet/10314488
La primera impresión no es la que cuenta
Cepeda, R. M. A. V., & Martín, F. J. C. (2022) · Diabetes práctica · doi:10.52102/diabet/pract/2022.1/art4
Control of Blood Glucose and Cardiovascular Risk Profile
Ciardullo, S., & Perseghin, G. (2023) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-031-13009-0_28
Anderzén, J. (2023) · Linköping University medical dissertations · doi:10.3384/9789180750325
Zhang, L., Guo, Y., Yang, Z., Li, J., Yan, W., & Xu, H. (2023) · Research Square · doi:10.21203/rs.3.rs-2577924/v1
Dart, A. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_32
Jacobsen, L. M., Sherr, J. L., Considine, E. G., Chen, A., Peeling, S., Hulsmans, M., Charleer, S., Urazbayeva, M., Tosur, M., ALAMARIE, S. A., et al. (2023) · medRxiv · doi:10.1101/2023.04.15.23288624
Mannucci, E., & Scoccimarro, D. (2023) · Practical issues in geriatrics · doi:10.1007/978-3-031-28061-0_23
Zozulińska‐Ziółkiewicz, D., Malecki, M. T., Czupryniak, L., Jarosz-Chobot, P. A., Klupa, T., Myśliwiec, M., Szadkowska, A., Szypowska, A., Gawrecki, A., Mianowska, B., et al. (2021) · Current Topics in Diabetes · doi:10.5114/ctd/146220
Dunn, T. B., & Redfield, R. R. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_70
Long-Term Pancreas Graft Function
Gruessner, A. C. (2023) · Springer eBooks · doi:10.1007/978-3-031-20999-4_73
Heald, A. H., Warner-Levy, J. J., Belston, L., Habte‐Asres, H. H., Horne, L., Metters, A., Whyte, M., & Gibson, M. (2023) · Cardiovascular Endocrinology & Metabolism · doi:10.1097/xce.0000000000000293
Bastos, C., Sumita, N. M., Vieira, A. O., Mendes, M. E., Lopes, R. M., Moresco, R. N., Nery, K., Souto-Santos, B. C. A., Brazão, F. V., & Poloni, J. A. T. (2023) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2023-1207
Diabetes Care in the Oncologic Population
Presswala, L. S., Farooki, A., & Flory, J. (2023) · Contemporary Endocrinology · doi:10.1007/978-3-031-44648-1_24
Developing Strategies to Improve Diabetes Management in College-Going Young Adults
(2024) · Frontiers research topics · doi:10.3389/978-2-8325-4815-8
Transitioning Adolescents and Young Adults with Type 1 Diabetes to Adulthood
D’Amico, R., & Buschur, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-54281-7_29
Treatment Strategies for Type 1 Diabetes
Childs, B. P., & Kruger, D. F. (2017) · American Diabetes Association eBooks · doi:10.2337/9781580405690.ch06
Rzayeva, R. A., Каримова, Н., Abbasova, M., & Gurbanov, Y. Z. (2024) · World of Medicine and Biology · doi:10.26724/2079-8334-2024-3-89-149-152
Impacto del inicio de la monitorización flash de glucosa en pacientes adultos con diabetes tipo 1
Sahagún, R. J. (2024) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/72390
Fredriksson, M., Persson, E., Möllsten, A., & Lind, T. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004709
Hyperglycemia worsens smooth muscle foam cell formation through PI3Kγ-dependent defective autophagyPreprint
Labrana, H., Wahart, A., Cormier, K., Solinhac, R., Swiader, A., Mentouri, I., Smirnova, N. F., Malet, N., Gayral, S., Ramel, D., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.21.634036
Kular, K. S., Gill, S. S., Manchanda, N., Rutledge, R., & Kular, K. S. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07754-3
Primary Care and Diabetes Technologies and Treatments
Simonson, G. D., Martens, T. W., Carlson, A. L., & Bergenstal, R. M. (2025) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2025.8810.gds
Analyzing the Advantages of Digital Technologies for Managing Diabetes
Galanki, V., Manaswini, V. K., Kethineedi, G. S. V. S. P. G., & Moora, S. (2025) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3349
Unni, S. R., Harthy, S. A., Singh, J., & McCallum, M. (2025) · Journal of Diabetes and Endocrine Practice · doi:10.1055/s-0045-1808263
Spring Meeting of the Young Researchers of SID, SIGG, SIIA, SIMI, SIPREC, SISA
D’Ardes, D., Bianconi, V., Dalt, L. D., D’Onofrio, L., Macchi, C., Visco, V., Cappelluti, M. A., Parrotta, I., Greco, C., Bencivenga, L., et al. (2025) · European Atherosclerosis Journal · doi:10.56095/eaj.v4i1.89
Giha, H. A., Sater, M. S., & Qarni, A. A. A. (2025) · Minerva Endocrinology · doi:10.23736/s2724-6507.25.04230-7
Optimising cardiac surgery outcomes in people with diabetes: the OCTOPuS pilot feasibility study
Holt, R. I. G., Barnard-Kelly, K. D., Patel, M. A., Newland‐Jones, P., Luthra, S., Picot, J., Partridge, H., & Cook, A. (2025) · Health Technology Assessment · doi:10.3310/poyw3311
Cardiovascular Outcome Trials in Type 1 Diabetes: We Are Not There Yet
Hirsch, I. B., & Eckel, R. H. (2025) · Diabetes Care · doi:10.2337/dci25-0062
Yang, W., Lin, C., Cai, X., Li, Z., Lv, F., Yang, W., Liu, G., Yang, X., Li, S., & Ji, L. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02926-y
Sebastián‐Valles, F., Alday, I. H., Lobariñas, L. E. L., Palacios‐Berraquero, M. L., Hierro, J. G., Gómez, G. L. R., Muñiz, Á. M., Navas-Moreno, V., de Icaya, P. M., Raposo‐López, J. J., et al. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70114
Tavares, C. E. C., Ribeiro, L. Z., Malerbi, F. K., Nakayama, L. F., & Regatieri, C. V. (2025) · Revista Brasileira de Oftalmologia · doi:10.37039/1982.8551.2025s3ex0003
Attaining Comprehensive Diabetes Care in Ghana: Insights of Policymakers and Diabetes Experts
Yorke, E., Akpalu, J., & Atiase, Y. (2025) · Current Medical Issues · doi:10.4103/cmi.cmi_83_25
AlSudais, H., AlSulaiman, T., Alotaibi, B. A., Alshalani, A., Almuqrin, A., Albakr, R. B., & Aldali, J. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227985
Endocrine-related neurological function recovery in pancreatic transplantation
Wang, S.-Y., Li, Z.-M., Zhang, M.-Z., Chen, Z., Liu, X., Li, Y., Li, P., Yang, G., Xia, Y., & Xu, T. (2025) · World Journal of Transplantation · doi:10.5500/wjt.v15.i4.106812
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26751167
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26751179
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26751173
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26751176
Petria, I., ALBUQUERQUE, S., Varoquaux, G. P., Vie, J.-J., Venteclef, N., Mohammedi, K., Roussel, R., Camoin, M., Perseghin, G., Velho, G., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21582085
Sanchez, M., Kannengiesser, C., Hoang, S., Potier, L., Fumeron, F., Venteclef, N., Scheen, A. J., Gautier, J., Hadjadj, S., Marre, M., et al. (2022) · Figshare · doi:10.6084/m9.figshare.21316169
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26333297
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26333439
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26751170
Lin, Z., He, J., Yuan, S., Song, C., Bian, X., Yang, M., & Dou, K. (2024) · Figshare · doi:10.6084/m9.figshare.24954450
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26751182
Slingerland, S. R., Schulz, D. N., van Steenbergen, G. J., Soliman-Hamad, M. A., Kisters, J. M. H., Timmermans, M., Teeuwen, K., Dekker, L., & van Veghel, D. (2024) · Figshare · doi:10.6084/m9.figshare.26751164
Diabetes: A Subspecialty of Medicine and a Matter of Public Health
Conway, R. B. (2025) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s580012
Wu, C.-Y., Lai, C., Ho, C., Wu, Y.-C., Liao, K., Wang, J.-J., Wang, D.-C., & Liang, F. (2026) · Journal of Diabetes Research · doi:10.1155/jdr/1437417 · Cited by 1
Delaying the Onset of Type 1 Diabetes—A Review of Current Protocols and Looking at Future Options
Griffin, R., & Smith, A. (2026) · Physician Assistant Clinics · doi:10.1016/j.cpha.2025.10.003
Glycemic management in adults with type 1 diabetes
Koliaki, C. C., & Liatis, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00317-4
Oltre i target glicemici: effetto legacy e variabilità glicemica nelle complicanze del diabete
Barone, S., & Sacchetta, L. (2026) · L Endocrinologo · doi:10.1007/s40619-026-01765-7
Mottalib, A., Alsibai, K., Salah, T., Fallaha, M. Y., Tomah, S., Middelbeek, R. J. W., Elseaidy, T., Brown, F. M., & Hamdy, O. (2026) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2026.03.010
Liu, V. B., Sue, L. Y., Byrd, T. F., Padilla, O. M., & Wu, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-9067817/v1
Molveau, J. (2025) · theses.fr (ABES) · doi:10.70675/bd2bda54z3647z4fc4z9eebz1d71ad50a8b2
Popovic, D. S., Κender, Ζ., & Koufakis, T. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70226
Kim, H. Y., Ji, E., & Kim, J. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113285
Yanovskaya, E. A., & Яновская, М. Е. (2026) · FOCUS Endocrinology · doi:10.62751/2713-0177-2026-7-1-05
Dyslipidemia in Pediatric Diabetes
Williams, K. M., & Ham, J. N. (2026) · Contemporary Endocrinology · doi:10.1007/978-3-032-17036-1_11
Lucove, J. C., CORNELIUS, E. M., Nguyen, H. T., Shah, V. N., Sherr, J. L., Kudva, Y. C., Carlson, A. L., & Wolf, W. A. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261444998
Artificial Intelligence Models to Help Process Medical Data
Gandikota, N., Kim, S., Vibert, B., East, T., & Berry, S. D. (2026) · Springer eBooks · doi:10.1007/978-3-032-19116-8_7
Current State of Cardiorenal Disease in People with Type 1 Diabetes
Fernandes, S., Hettinger, B., Ang, L. P., & Pop‐Busui, R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.004
Ni, H., SNAITH, J. R., & Greenfield, J. R. (2026) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2026.04.001
Herranz-Antolín, S., Gomez-Peralta, F., Xu, Y., Martínez‐Brocca, M. A., Molina, G. C., Alonso, A. A., Brito-Sanfiel, M. Á., Martínez‐Montoro, J. I., Bellido, V., Azriel, S., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261451052
Liu, C., Renström, F., Gastaldi, G., Brändle, M., & Bilz, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1819019
Chatzakis, C., Mansukhani, T., Mitsigiorgi, R., May, E., & Nicolaides, K. H. (2026) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2026.103440
Mikrovaskuläre Komplikationen bei Typ-1-Diabetes
Schmidt, A.-S., & Ebert, T. (2026) · CardioVasc · doi:10.1007/s15027-026-4013-4
Longo, M., Maio, A., Tomasuolo, M., Nuzzo, M. D., Forestiere, D., Castaldo, F., Caruso, P., Scappaticcio, L., Maiorino, M. I., Bellastella, G., et al. (2026) · Diabetology · doi:10.3390/diabetology7060113
Cooper, D., Ubben, T., Knoll, C., Blume, C., Neumann, W., & Braune, K. (2026) · SLEEP Advances · doi:10.1093/sleepadvances/zpag066
Hyperlipidaemia in youth with type 1 diabetes: Are current guidelines clinically useful?
Rodrigues, F., White, M., & O’Connell, M. A. (2026) · Diabetic Medicine · doi:10.1111/dme.70382
Pyatak, E. A., Schneider, S., Hernandez, R., Hoogendoorn, C. J., Hawkins, M., & Gonzalez, J. S. (2026) · Diabetes Care · doi:10.2337/dc26-0603
Song, Y. W., Lin, Z., He, J. I., Fu, R., & Dou, K. (2026) · Journal of the American Heart Association · doi:10.1161/jaha.126.051797
Schleicher, E., Müller-Wieland, D., Nauck, M., Merz, T., Heinemann, L., & Freckmann, G. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2896-0406
HOOVEN-DAVIS, J. T., Lalama, C. M., SYER, S. A., Rothenberger, S. D., Libman, I. M., & March, C. A. (2026) · Diabetes Care · doi:10.2337/dc26-0634
Zhou, J., Mychaleckyj, J. C., Haddad, F., Costacou, T., Orchard, T. J., & Miller, R. G. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03313-x
Lactate promotes macrophage-derived foam cell formation and atherosclerosis
Jia, Z., Liu, S., Yang, Z., Chen, X., Liu, Y., Li, S., Chen, J., Feng, X., Niu, X., & Wang, W. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.121858
Legault, L., Sherr, J. L., Davis, E. A., Cerezales, M., Mirón, A. K., Syleouni, M., & Ng, S. M. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261486122
Arık, S. D., & Çetinkaya, S. (2026) · Journal of Pediatric Endocrinology & Metabolism (JPEM) · doi:10.1515/jpem-2026-0197
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06833-z
Nehme, M., Samuna, I. B., Messier, V., Dawe, P., Brazeau, A., & Taleb, N. (2026) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2026.109417
Metadata
- Authors
- The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group
- Corresponding author
- The Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-02-09
- Volume
- 39
- Issue
- 5
- Pages
- 686-693
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4839174
- OpenAlex
- W2346630656
- Cited by
- 712
- References
- 39
- Citations by year
- 2026: 60 · 2025: 77 · 2024: 78 · 2023: 63 · 2022: 88 · 2021: 57 · 2020: 67 · 2019: 79 · 2018: 65 · 2017: 56 · 2016: 22
- FWCI
- 74.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Disease
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, tight glycemic control, cardiovascular disease, long-term cardiovascular outcomes, HbA1c, albuminuria, myocardial infarction, stroke, cardiovascular mortality, Diabetes Control and Complications Trial
- MeSH terms
- Adolescent, Adult, Cardiovascular Diseases, Diabetes Mellitus, Type 1, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Male, Risk Factors, Cohort Studies, Incidence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
